Articles
🔒 Members Only · Compliance & Enforcement BriefYou’ve reached the member portion of this brief.Members read the full analysis and the source documents in every Brief, six days a week.
PPP Enforcement Actions Gather Steam
Do Your Diligence: M&A Considerations Following OIG’s Special Fraud Alert on Telemedicine
Eli Lilly Accused of Defrauding Government in $60 Million Qui Tam Suit
Commerce Department Tacks to New Aggressive Enforcement Program
DOJ Procurement Collusion Strike Force Revs Up in 2022
Second Circuit Agrees that the Anti-Kickback Statute Does Not Contain a “Corruption” Element
Sign on the Dotted Line: Compliance Certifications by CEOs and CCOs a Likely Requirement
This Retaliation Claim Survived Under State Law, but Not the FCA
Suspect Characteristics Identified under a Telehealth Special Fraud Alert
Organizational Conflicts of Interest – Part 1: A Refresher on OCIs
Pushing Back on Kickbacks: $900 Million Settlement in Biotech False Claims Act Case
Second Circuit: Anti-Kickback Statute Liability Doesn’t Require Corrupt Intent
Court Filing Reveals that DOJ Is Investigating Fintech’s Administration of PPP Loans
DOJ Supporting Appeal of Allergan Sales Ruling over FCA Scienter Standards
Download Now – How to Request an Advisory Opinion (and Why)
The 5 Biggest Hurdles to Effective ESG Reporting
The CCO’s Role in an Effective Compliance Program
Biotronik Anti-Kickback Enforcement Action: Bribery Schemes and Lessons Learned
Seventh Circuit Suggests High Standard Under the FCA Whistleblower Retaliation Provision
Keep reading
